Nano - Perle

"Wir sind sehr aufgeregt, mit Thermo Fisher Scientific Sonde für unsere Technologie", sagte Howard Birndorf, CEO von Nanogen. "Unsere proprietäre Technologie Sonde hat bewiesen, um bessere Ergebnisse zu erzielen als mit den traditionellen Sonde PCR-Technologie. Wir sind stolz darauf, zu dienen, die Rasch wachsenden Bedürfnissen der Forschungs-Marktes durch Partner wie Thermo Fisher, die helfen können die Forscher voraus grundlegende Biologie und der Entwicklung neuer Therapeutika. "



Quelle / mehr: translate.google.com/translate?  u=www.nanogen.com/presscenter/pressreleases/...&langpair=en%7Cde

www.nanogen.com/

DRI Capital Inc. Acquires Royalties from Nanogen Inc. for US $10 Million
Mar 31, 2008

TORONTO, ONTARIO and SAN DIEGO, CALIFORNIA, March 31, 2008 – DRI Capital Inc. (DRI) and Nanogen Inc. (Nasdaq: NGEN) announced today that they have entered into an agreement for DRI to acquire, for US$10 million, all future royalties generated by Applied Biosystems (ABI) under a license ABI has taken from Nanogen for MGB™ (minor groove binder) technology.  

“This transaction extends DRI’s interests in royalties related to molecular biology research tools” said Joshua Salisbury, Managing Director at DRI.  “This agreement is another example of the tailored and innovative sources of capital DRI offers and we are pleased that we were able to work with Nanogen again.”
“Monetizing this royalty stream provides us with a non-dilutive means of raising capital to fund our operations as we work towards achieving cash flow breakeven in late 2008.” said Howard C. Birndorf, Nanogen chairman and chief executive officer.

The royalty payments included in the agreement are related to Nanogen’s patented MGB™ technology that has been licensed to ABI for use in ABI’s TaqMan® products (TaqMan® is a registered trademark of Roche Molecular Systems, Inc.).  ABI’s TaqMan® assays library using Nanogen’s MGB™ is the leading life science research product library for PCR applications.  Nanogen’s MGB™ technology provides many advantages in the design of oligonucleotide probes, and has become a sought after component for many companies working in the molecular detection and diagnostic marketplace.  Nanogen has an active partnering and licensing program and has more than 40 patents related to nucleic acid detection.

Quelle / mehr: www.nanogen.com/presscenter/pressreleases/5184/

Übersetzung: translate.google.com/translate?u=http://...0/&langpair=en%7Cde

Siehe news!!!

ja che. Du hast uns lieb, wir dich auch.
Aber halt einfach mal die Klappe.
Von Börse verstehst du nichts.

.......... nein, ich halte meine "Klappe" nicht!
Klicke mich doch einfach nicht an, dann brauchst Du auch nichts von mir lesen.

Übrigens, für das, dass ich nichts von der Börse verstehe, lebe ich nicht schlecht von Ihr. :-)))

Bzgl. Nanogen: Du bist einfach zum falschen Zeitpunkt eingestiegen, damals habe ich verkauft. Nun bin ich wieder eingestiegen und mache Gewinn und muß mir Dein Expertengeschwätz anhören ..........

.... hauptsache die Zahlen stimmen ;-)

Nanotechnische Grüße
cheche

http://www.nanogen.com/presscenter/pressreleases/5368/

Quelle / Übersetzung: http://translate.google.com/translate?u=http://...8/&langpair=en%7Cde

ganz herausragend!
Und der Kurs schmiert weiter ab!
Soviel zur Bedeutung solcher Meldungen.

nein, cheche wird mich nicht liebhaben.
Ich nenne Nanogen einfach Nanomüll.

Diagnostik-Test für Influenza und der Vogelgrippe

http://translate.google.com/translate?u=http://...8/&langpair=en%7Cde

http://www.nanogen.com/presscenter/pressreleases/5428/

Dutton Associates Announces Investment Opinion: Nanogen Strong Speculative Buy Rating In Update Coverage By Dutton Associates
16:35 23.06.08

ROSEVILLE, Calif.--(BUSINESS WIRE)--

Dutton Associates updates its coverage of Nanogen (Nasdaq:NGEN) maintaining a Strong Speculative Buy rating and a $1.00 price target. The 12-page report by Dutton senior analyst Wayne T. Lottinville, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.

Quelle / mehr: http://www.ariva.de/...overage_By_Dutton_Associates_n2664836?secu=925

hat jemand news zu nanogen? Lohnt hier ein investment?

"Our third quarter results continue to show the excellent progress we are making as a result of our business restructuring. Compared to one year ago, we experienced a substantial reduction in spending while continuing our strong revenue growth," said Howard C. Birndorf, Nanogen's chairman of the board and CEO. "This continuing improvement in business operations, combined with the planned merger with Elitech in early 2009, will complete the transformation of Nanogen into a profitable, global in-vitro diagnostics company."

Financial Guidance for 2008:

Nanogen's 2008 guidance is unchanged. The company expects total 2008 revenues to increase by approximately 25 percent from 2007 levels with a gross margin of approximately 60 percent. The anticipated growth in revenues, combined with improved gross margins and substantial operating expense reductions, should allow the company to continue to improve quarterly operating cash flow through the end of 2008 as measured by Modified EBITDA.

Modified EBITDA continued to improve during the third quarter of 2008. Management remains committed to continuing to improve this measure of performance.

ist das noch Aktuell

www.bio.vobs.at/gen-mol/g-krimi-4.htm

gruss macos

Nanogen Licenses Molecular Technology to Quest Diagnostics for In Vitro Diagnostic Testing
Mar 4, 2009

SAN DIEGO (March 04, 2009) – Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and rapid diagnostic products, announced today that it has signed an end user license agreement (EULA) with Quest Diagnostics for use of the Company’s proprietary MGB Probe technology in human in vitro diagnostic testing.   Under the licensing agreement, Quest Diagnostics will have rights to use and sell products and services incorporating the MGB Probe technology.  Terms of the EULA include an upfront fee and royalties paid on tests sold using the licensed technology.



“We’re proud that Quest Diagnostics, the world’s leader in diagnostic testing, is using our proprietary minor groove binder (MGB) technology and incorporating it into some of their laboratory developed molecular tests,” said Merl Hoekstra, Nanogen’s Vice President of Corporate and Business Development.  “We’re proud of the growing reputation and the expanding base of licensed end users of our technology.”



The Company’s MGB Probe technology is broadly licensed in the research and clinical fields and accounts for a majority of the Company’s revenue today.  Nanogen has more than 40 reagent and kit products sold for in vitro diagnostic use under the MGB Alert® and Q-PCR Alert™ brands.  End users who use or would like to use our proprietary technology should contact our licensing group to obtain a EULA.

DRI Capital is a privately held investment management company, focused on the healthcare industry, with over US$1 billion under management. DRI Capital currently manages two funds: the Royalty Monetization Fund and the Structured Finance Fund.
The Royalty Monetization Fund acquires existing royalty streams at competitive rates from companies, institutions and inventors. DRI Capital is a leader in monetizing royalties, having acquired over US$850 million in royalty-based cash flows on commercialized products. In 2007 alone, DRI Capital has deployed about US$450 million with royalty acquisitions on products such as Enbrel, Flumist, Preotact and PEG-INTRON.
The Structured Finance Fund, launched in January 2008 with approximately US$300 million, is a hybrid debt and equity fund which invests in commercial stage healthcare products through investments in synthetic royalties, debt, and structured debt/equity instruments. The fund focuses on commercial stage pharmaceuticals and medical devices and is not limited to a therapeutic category or market segment. The financing that the Structured Finance Fund provides, which is primarily non-dilutive, allows for companies to finance in-licensing and new product acquisitions, sales force expansions, or fund additional capital needs.
www.dricapital.com

For the quarter ended December 31, 2008, Nanogen reported a net loss of $2.0 million, or $0.02 per share, compared to a net loss of $6.5 million or $0.09 per share for the same quarter in 2007, and a net loss of $6.0 million or $0.08 per share in the third quarter of 2008.   For the full year of 2008, the net loss was $38.1 million versus $33.9 million in 2007.



Nanogen's consolidated cash, cash equivalents and short-term investments balance at the end of the fourth quarter of 2008 was approximately $3.1 million.  



“Our strategy and related restructuring has clearly improved the performance of our business,” said Howard Birndorf, chairman and chief executive officer. “However, our available cash resources are not adequate to support our 2009 plan and therefore, we are aggressively continuing our efforts with Cowen & Co. to identify and evaluate strategic opportunities for our business. This effort is one of our highest priorities.”  

In order to conserve its limited cash resources, the company has deferred the audit of its financial statements for the year ended December 31, 2008.  Accordingly, the company does not expect to file its Form 10-K by March 31, 2009, the applicable deadline under the applicable rules of the Securities and Exchange Commission.  

About Nanogen, Inc.

Nanogen’s in vitro diagnostic products provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents and a line of rapid, point-of-care diagnostic tests. For additional information please visit Nanogen’s website at www.nanogen.com.



Cautionary Statement: This press release contains forward-looking statements based on the company’s current expectations. These forward-looking statements include, without limitation, references to the company’s performance and completion of a strategic transaction.  Actual results may differ materially from these forward-looking statements due to a number of factors and, consequently, you should not rely on such forward looking statement as prediction of future event.  These factors include, but are not limited to, the company’s available cash resource and ability to pay its trade obligations, the willingness of vendors to continue supplying services and materials to the company, the occurrence of defaults under the company’s convertible notes and other obligations, potential creditors actions against the company, including commencing an insolvency proceeding, ability to maintain its Nasdaq listing, and other risks and uncertainties discussed under the caption “Risk Factors” in the company’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof.   The company disclaims any intent or obligation to update these forward-looking statements.

die ist doch so gut wie futsch oder nicht?